Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Debra Hoppensteadt PhD"'
Autor:
Fakiha Siddiqui BDS, Alfonso Tafur MD, MS, MBA, Amir Darki MD, Bulent Kantarcioglu MD, Debra Hoppensteadt PhD, Emily Krupa BS, Omer Iqbal MD, Jawed Fareed PhD, Manuel Monreal MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 30 (2024)
Pulmonary embolism (PE) is a heterogenous condition with variable clinical presentations. Thrombin generation potential (TGP) and biomarkers, and blood cellular indices can reflect the underlying pathophysiology and risk stratification of PE. This ca
Externí odkaz:
https://doaj.org/article/59c1ad82c4924d33aa568ed856fbda76
Autor:
Pranathi Karumanchi BS, Divya Sridharan BS, Debra Hoppensteadt PhD, Fakiha Siddiqui BDS, PhD candidate, Jawed Fareed PhD, Vinod Bansal MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 30 (2024)
Cardiovascular disease is a prevalent complication in patients with end-stage renal disease (ESRD) on maintenance hemodialysis. In the ESRD patient population, cardiovascular mortality is 20 times higher compared to the general population. The strong
Externí odkaz:
https://doaj.org/article/5a4c8305d0874bd891d731f5712d7421
Autor:
Fakiha Siddiqui BDS, Debra Hoppensteadt PhD, Walter Jeske PhD, Eduardo Ramacciotti MD, PhD, Alfonso Tafur MD, MS, MBA, Jawed Fareed PhD, FAHA
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 30 (2024)
Introduction Andexanet alfa (AA) - zhzo, recombinant coagulation factor Xa, is an approved antidote for oral Xa inhibitors (apixaban and rivaroxaban). Unfractionated heparin (UFH) is commonly used for therapeutic, interventional, and surgical indicat
Externí odkaz:
https://doaj.org/article/b626561e959842a89b3955e3da6842d6
Autor:
Madeline Allen BS, Vinod Bansal MD, Fakiha Siddiqui BDS, Debra Hoppensteadt PhD, Emily Krupa BS, Jawed Fareed PhD, Bulent Kantarcioglu MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
En-stage renal disease (ESRD) is a growing public health problem. The atherosclerotic cardiovascular complications are the leading causes of mortality and morbidity in the ESRD. In this study, we sought to quantify the levels of thrombo-inflammatory
Externí odkaz:
https://doaj.org/article/1484f6f45c4d4224bb6a176386ef2c66
Autor:
Alexander O’Hara BS, Jacob Pozin BS, Amir Darki MD, MSc, Fakiha Siddiqui BDS, Debra Hoppensteadt PhD, Jeanine Walenga PhD, Jawed Fareed PhD, Bulent Kantarcioglu MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Type I and type II diabetes are closely associated with a pro-inflammatory state and to a pro-thrombotic state. The role of glycemic control in pulmonary embolism (PE) is poorly understood and requires additional investigation. The aim of this study
Externí odkaz:
https://doaj.org/article/b6d3e73ab61346bcbbc66709c9086fdb
Autor:
Ameer Odeh BS, Gabriel D. Dungan BS, Debra Hoppensteadt PhD, Fakiha Siddiqui PhD, Bulent Kantarcioglu MD, Amir Darki MD, Jawed Fareed PhD, Mushabbar A. Syed MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Introduction Atrial Fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide. Inflammation and structural remodeling of the left atrium are thought to be involved in the pathogenesis of AF. This study explores collagen remodeling and infl
Externí odkaz:
https://doaj.org/article/9a7f4e98c2b34130acfdde569354cf47
Autor:
Guy Olson BS, Walter Jeske PhD, Omer Iqbal MD, Emily Krupa BS, Amber Farooqui MD, Fakiha Siddiqui BDS, Debra Hoppensteadt PhD, Ahmed Kouta PhD, Jawed Fareed PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Introduction: Bovine and ovine mucosa represent alternate anticoagulants to porcine mucosa for production of unfractionated heparin (UFH). Standardized heparins from various sources can be blended and potency adjusted, blended heparins exhibit compar
Externí odkaz:
https://doaj.org/article/a22e14aa5cf148389f9dbf9a742d529d
Autor:
Yevgeniy Brailovsky DO, MSc, Vladimir Lakhter DO, Joshua Newman MD, Sorcha Allen MBBCh, Ahmed Elkaryoni MD, Parth Desai MD, Dalila Masic PharmD, Carlos F. Bechara MD, Emily Bontekoe BS, Debra Hoppensteadt PhD, John J. Lopez MD, Fakiha Siddiqui BDS, Omer Iqbal PhD, Jawed Fareed PhD, Amir Darki, MD, MSc
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Background Acute pulmonary embolism (PE) is a heterogeneous disease process with variable presentation and outcomes. The endogenous fibrinolytic system is a complex framework of regulatory pathways that maintains homeostasis by dissolving overabundan
Externí odkaz:
https://doaj.org/article/7f1e6de3abd5418699902e753ad986f7
Autor:
Ameer Odeh BS, Gabriel D. Dungan BS, Amir Darki MD, Debra Hoppensteadt PhD, Fakiha Siddiqui PhD, Bulent Kantarcioglu MD, Jawed Fareed PhD, Mushabbar A. Syed MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022)
Introduction Atrial Fibrillation (AF) is the most common cardiac arrythmia in the world. Structural remodeling and fatty acid metabolism dysregulation are believed to play a role in the development of AF. This study explored different biomarkers in t
Externí odkaz:
https://doaj.org/article/68398fadd3244e98a7a67cf33fd74789
Autor:
Siddharth Mehrotra, Debra Hoppensteadt PhD, Walter Jeske PhD, Fakiha Siddiqui BS, Omer Iqbal MD, Alfonso Tafur MD, Bruce Lewis MD, Mark Jaradeh BS, Bulent Kantarcioglu MD, Jawed Fareed PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022)
Introduction The available oral anti-Xa agents are routinely used for the management of thrombotic disorders. A molecularly modified recombinant coagulation FXa, also known as Andexanet Alfa (AA), that has been developed as an antidote to neutralize
Externí odkaz:
https://doaj.org/article/ea1b4598519b4811bd1e31d03d5eacd1